Ardelyx, Inc. (ARDX)
NASDAQ$5.42
Market Cap
$1.29B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
83 of 925
Rank in Industry
61 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ARDX Insider Trading Activity
ARDX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $3,374,588 | 4 | 6 |
Sells | $11,916,965 | 61 | 94 |
Related Transactions
| MOTT DAVID M | director | 4 | $3.37M | 0 | $0 | $3.37M |
| Rodriguez Susan | Chief Commercial Officer | 0 | $0 | 1 | $52,357 | $-52,357 |
| Renz Justin A | Chief Financial Officer | 0 | $0 | 4 | $125,650 | $-125,650 |
| Blanks Robert | See Remarks | 0 | $0 | 4 | $317,022 | $-317,022 |
| Rosenbaum David P. | Chief Development Officer | 0 | $0 | 11 | $1.37M | $-1.37M |
| Williams Laura A | Chief Medical Officer | 0 | $0 | 6 | $1.51M | $-1.51M |
| Felsch Robert Ora | See Remarks | 0 | $0 | 3 | $1.88M | $-1.88M |
| RAAB MICHAEL | President & CEO | 0 | $0 | 25 | $2.92M | $-2.92M |
| GRAMMER ELIZABETH A | See Remarks | 0 | $0 | 7 | $3.75M | $-3.75M |
About Ardelyx, Inc.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing …
Insider Activity of Ardelyx, Inc.
Over the last 12 months, insiders at Ardelyx, Inc. have bought $3.37M and sold $11.92M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $2.13M and sold $5.47M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $3.37M.
The last purchase of 77,729 shares for transaction amount of $388,738 was made by MOTT DAVID M (director) on 2025‑02‑24.
List of Insider Buy and Sell Transactions, Ardelyx, Inc.
| 2025-03-07 | Sale | RAAB MICHAEL | President & CEO | 41,668 0.0176% | $5.36 | $223,199 | +2.45% | |
| 2025-02-24 | MOTT DAVID M | director | 77,729 0.0322% | $5.00 | $388,738 | +3.70% | ||
| 2025-02-20 | Sale | RAAB MICHAEL | President & CEO | 22,964 0.0086% | $5.62 | $129,124 | -6.36% | |
| 2025-02-20 | Sale | Williams Laura A | Chief Medical Officer | 4,941 0.0018% | $5.62 | $27,783 | -6.36% | |
| 2025-02-20 | Sale | Renz Justin A | Chief Financial Officer | 5,171 0.0019% | $5.62 | $29,077 | -6.36% | |
| 2025-02-20 | Sale | GRAMMER ELIZABETH A | See Remarks | 4,291 0.0016% | $5.62 | $24,128 | -6.36% | |
| 2025-01-31 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.0176% | $5.36 | $223,355 | +1.49% | |
| 2025-01-21 | MOTT DAVID M | director | 199,000 0.0854% | $4.99 | $992,672 | +10.95% | ||
| 2025-01-07 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.0174% | $5.31 | $221,309 | +0.37% | |
| 2024-12-19 | MOTT DAVID M | director | 213,300 0.0889% | $4.67 | $996,580 | +14.29% | ||
| 2024-12-10 | Sale | RAAB MICHAEL | President & CEO | 25,000 0.0105% | $5.26 | $131,620 | +1.14% | |
| 2024-11-25 | Sale | RAAB MICHAEL | President & CEO | 25,000 0.0107% | $5.38 | $134,483 | +2.00% | |
| 2024-11-20 | Sale | RAAB MICHAEL | President & CEO | 31,980 0.0132% | $4.79 | $153,328 | +8.74% | |
| 2024-11-20 | Sale | Blanks Robert | See Remarks | 4,941 0.002% | $4.79 | $23,690 | +8.74% | |
| 2024-11-20 | Sale | Williams Laura A | Chief Medical Officer | 7,366 0.003% | $4.79 | $35,316 | +8.74% | |
| 2024-11-20 | Sale | Renz Justin A | Chief Financial Officer | 5,260 0.0022% | $4.79 | $25,219 | +8.74% | |
| 2024-11-20 | Sale | GRAMMER ELIZABETH A | See Remarks | 7,046 0.0029% | $4.79 | $33,782 | +8.74% | |
| 2024-11-20 | Sale | Rosenbaum David P. | Chief Development Officer | 7,184 0.003% | $4.79 | $34,444 | +8.74% | |
| 2024-11-13 | MOTT DAVID M | director | 215,868 0.0924% | $4.62 | $996,598 | +18.22% | ||
| 2024-11-11 | Sale | RAAB MICHAEL | President & CEO | 2,743 0.0012% | $4.90 | $13,441 | +8.69% |
Total: 354
*Gray background shows transactions not older than one year
Insider Historical Profitability
37.37%
| MOTT DAVID M | director | 2015494 0.8456% | $10.92M | 12 | 0 | +19.65% |
| RAAB MICHAEL | President & CEO | 1635138 0.686% | $8.86M | 1 | 56 | +248.1% |
| Williams Laura A | Chief Medical Officer | 303804 0.1275% | $1.65M | 1 | 15 | +248.1% |
| Renz Justin A | Chief Financial Officer | 285968 0.12% | $1.55M | 1 | 20 | +248.1% |
| GRAMMER ELIZABETH A | See Remarks | 181043 0.076% | $981,253.06 | 2 | 41 | +117.06% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,217,280 | 112 | 46.33% | $1.31B | |
$831,902,292 | 108 | 9.34% | $1.56B | |
$20,297,544 | 73 | 103.06% | $1.58B | |
$54,590,806 | 65 | 21.84% | $1.25B | |
Ardelyx, Inc. (ARDX) | $1,101,324,300 | 58 | 37.37% | $1.29B |
ARDX Institutional Investors: Active Positions
| Increased Positions | 122 | +53.98% | 22M | +15.34% |
| Decreased Positions | 98 | -43.36% | 13M | -9.01% |
| New Positions | 47 | New | 8M | New |
| Sold Out Positions | 36 | Sold Out | 3M | Sold Out |
| Total Postitions | 250 | +10.62% | 151M | +6.33% |
ARDX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Janus Henderson Group Plc | $130,719.00 | 10.25% | 24.39M | +3M | +13.28% | 2024-12-31 |
| Blackrock, Inc. | $99,275.00 | 7.78% | 18.52M | +694,542 | +3.9% | 2024-12-31 |
| Vanguard Group Inc | $76,984.00 | 6.04% | 14.36M | +767,111 | +5.64% | 2024-12-31 |
| State Street Corp | $62,138.00 | 4.87% | 11.59M | -548,936 | -4.52% | 2024-12-31 |
| Macquarie Group Ltd | $55,458.00 | 4.35% | 10.35M | +1M | +15.62% | 2024-12-31 |
| Eventide Asset Management, Llc | $30,020.00 | 2.35% | 5.6M | -2M | -24.45% | 2024-12-31 |
| Geode Capital Management, Llc | $29,532.00 | 2.32% | 5.51M | +21,988 | +0.4% | 2024-12-31 |
| Millennium Management Llc | $15,884.00 | 1.25% | 2.96M | -1M | -26.13% | 2024-12-31 |
| Citadel Advisors Llc | $13,350.00 | 1.05% | 2.49M | +281,685 | +12.75% | 2024-12-31 |
| Morgan Stanley | $12,980.00 | 1.02% | 2.42M | -712,788 | -22.74% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.